Allison Betof Warner, MD, PhD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for patients with stage IIB and beyond melanoma.
Nivolumab/Ipilimumab Improves Real-World Melanoma Outcomes Vs Pembrolizumab
At 1 and 2 years, the progression-free survival rates were higher with nivolumab plus ipilimumab vs pembrolizumab in patients with cutaneous melanoma.
Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors
A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.
Pembrolizumab Regimen May Show Synergy in Melanoma Populations
Biomarker analyses and real-world comparisons to refine patient selection are ongoing in the phase 2 PLUME trial.
OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma
John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.
FDA Accepts Resubmission of BLA for RP1/Nivolumab in Advanced Melanoma
The agency has set a PDUFA date of April 10, 2026, for the decision on RP1 plus nivolumab in patients with previously treated advanced melanoma.
Cancer Vaccine/Pembrolizumab Improves PFS in Treatment-Naive Melanoma
A novel cancer vaccine, IO102-IO103, combined with pembrolizumab, showed promising results in improving PFS for advanced melanoma.